Can a cyclo-oxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin?
Authors:
- Anna LocatelliALAnna Locatelli
- Patrizia VerganiPVPatrizia Vergani
- Primula BelliniPBPrimula Bellini
- Nicola StrobeltNSNicola Strobelt
- Alessandro GhidiniAGAlessandro Ghidini
- 1 March 2001
- journal article
- research article
- Published by Elsevier in British Journal of Obstetrics and Gynaecology
- Vol. 108 (3) , 325-326
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Nimesulide and neonatal renal failureThe Lancet, 2000
- Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolyticThe Lancet, 1999
- Efficacy of the selective prostaglandin synthase type 2 inhibitor nimesulide in blocking basal prostaglandin production and delaying glucocorticoid-induced premature labor in sheepAmerican Journal of Obstetrics and Gynecology, 1999
- COX-2 inhibitorsThe Lancet, 1999
- Use of a cyclo-oxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm deliveryThe Lancet, 1997